About Protara Therapeutics, Inc.
Tenacious in our search for transformative therapies
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- New York, NY
- Founded
- 2017
- Company type
- Public Company
- Company profile name
- Protara Therapeutics
Protara is committed to advancing transformative therapies for people with cancer and rare diseases. Protara’s portfolio includes its lead program, TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, an investigational, intravenous phospholipid substrate replacement therapy in development for the treatment of intestinal failure-associated liver disease.
For more information, visit www.protaratx.com.
Specialties
- Rare Diseases
- Parenteral Nutrition
- Choline Deficiency
- Metabolic Diseases
- Orphan Diseases
- Gastrointestinal Diseases
- Short Bowel Syndrome
- Drug Development
- Corporate Development
- Non-Muscle Invasive Bladder Cancer
- and Lymphatic Malformations
Company locations
345 Park Avenue South, 3rd Floor, New York, NY 10010, US
Locations listed on the company profile. These may include offices outside the United States, and not every location is hiring.
On LinkedIn
- Followers
- 6,251
- People linked to this company
- 66
People who list this company on LinkedIn, not a verified employee count. Figures reflect the saved company profile.
Explore the company
Employer category
Other employer
Estimated from the company profile. This category has not been confirmed by the employer.